[1] Ross, H. J.; Kozono, D. E.; Urbanic, J. J.; Williams, T. M.; Dufrane, C.; Bara, I.; Gandhi, M.; Schulze, K.; Brockman, J. M.; Wang, X. F.; Vokes, E. E.; Stinchcombe, T., Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC. Journal of Clinical Oncology 2018, 36 (15_suppl), TPS8585-TPS8585.
[2] Antonia, S. J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K. H.; de Wit, M.; Cho, B. C.; Bourhaba, M.; Quantin, X.; Tokito, T.; Mekhail, T.; Planchard, D.; Kim, Y. C.; Karapetis, C. S.; Hiret, S.; Ostoros, G.; Kubota, K.; Gray, J. E.; Paz-Ares, L.; de Castro Carpeno, J.; Wadsworth, C.; Melillo, G.; Jiang, H.; Huang, Y.; Dennis, P. A.; Ozguroglu, M.; Investigators, P., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017, 377 (20), 1919-1929.
[3] Albain KS, S. R., Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD, Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374 (9687), 379-86.
[4] Butts C, S. M., Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C,; Schröder A, S. F. S. t. t., Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014, 15 (1), 59-68